Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from NCI has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

April 10, 2026

Vol.52 No.14

In Brief

Karmanos Cancer Institute becomes first free-standing cancer center to treat hemophilia B with new gene therapy

The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide a new hemophilia treatment. Etranacogene dezaparvovec-drlb, also known by its brand name Hemegenix, is a one-time gene therapy approved by FDA for the treatment of adults with hemophilia B.

April 03, 2026

Vol.52 No.13

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

Karmanos Cancer Institute becomes first free-standing cancer center to treat hemophilia B with new gene therapy

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Renew today!

Subscriber content

Never miss an issue!

Login

Khalil Choucair joins thoracic oncology and phase I clinical trials teams at Karmanos

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantageCancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

Karmanos Cancer Institute becomes first free-standing cancer center to treat hemophilia B with new gene therapy

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Never miss an issue!

Login

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine